B BRAUN MEDICAL
PharmaB BRAUN MEDICAL is a pharmaceutical company focused on Neurology, Infectious Disease, Dermatology. Key products include PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER.
Upcoming FDA Decisions
Full Calendar →B BRAUN MEDICAL's Key Drugs
B BRAUN MEDICAL's core commercial portfolio centers on PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MIDAZOLAM IN 0.8% SODIUM CHLORIDE, spanning Neurology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Intra-abdominal Infections
Complicated Skin and Skin Structure Infections
B BRAUN MEDICAL's Recent FDA Approvals
B BRAUN MEDICAL secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
B BRAUN MEDICAL's Therapeutic Areas
B BRAUN MEDICAL's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Infectious Disease, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
B BRAUN MEDICAL's Top Competitors
B BRAUN MEDICAL's closest competitors by therapeutic-area and drug-target overlap include Baxter, B BRAUN, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
B BRAUN MEDICAL Pipeline Snapshot
B BRAUN MEDICAL has 5 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 5 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (1)
Company Info
- First Approval
- 2015-04-30
- Latest
- 2025-10-24
- Applications
- 16